Related Experiment Video
Updated: Jun 6, 2026
03:42
A Murine Model of Hyperlipidemia-Induced Heart Failure with Preserved Ejection Fraction
Published on: March 29, 2024
Enhancing the metabolic substrate: PPAR-alpha agonists in heart failure
Satyam Sarma1, Hossein Ardehali, Mihai Gheorghiade
1Division of Cardiology, Department of Medicine, Northwestern Memorial Hospital, Northwestern University, 251 East Huron, Chicago, IL 60611, USA. s-sarma@md.northwestern.edu
Heart Failure Reviews
|November 25, 2010
Summary
PPARα agonists, like fibrates, may improve heart failure outcomes by boosting energy production and reducing harmful heart growth. These drugs enhance fatty acid oxidation, addressing the "energy-starved" heart in heart failure patients.
Area of Science:
- Cardiology
- Metabolic pathways
- Pharmacology
Background:
- Heart failure prognosis has improved, yet morbidity and mortality remain high.
- Current treatments focus on neurohormonal blockade and hemodynamics.
- Myocardial energy imbalance (demand vs. supply) is central to heart failure pathophysiology.
Purpose of the Study:
- To explore the potential of PPARα agonists in treating systolic heart failure.
- To investigate if PPARα agonists can augment myocardial ATP production.
- To assess the role of PPARα agonists in targeting maladaptive hypertrophic pathways.
Main Methods:
- Review of existing literature on PPARα agonists and heart failure.
- Analysis of preclinical data on fibrates' effects on fatty acid oxidation, fibrosis, and hypertrophy.
- Evaluation of the clinical safety profile of PPARα agonists.
Main Results:
- Down-regulation of fatty acid oxidation contributes to the "energy-starved" heart in heart failure.
- PPARα agonists enhance fatty acid oxidation in animal models.
- PPARα agonists have demonstrated improved endothelial function and reduced cardiac fibrosis/hypertrophy in preclinical studies.
Conclusions:
- PPARα agonists may offer a novel therapeutic strategy for systolic heart failure.
- Augmenting myocardial ATP production via enhanced fatty acid oxidation is a potential benefit.
- Targeting maladaptive hypertrophic pathways is another proposed mechanism of action.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:17Pathophysiology of Heart Failure
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...